John Poulos Joins Linden As Operating Partner
CHICAGO, Illinois (May 19, 2017) – Linden Capital Partners, a Chicago-based private equity firm focused exclusively on healthcare, today announced that John Poulos joined the firm as an Operating Partner. Mr. Poulos will serve as the lead Operating Partner supporting Linden’s pharmaceutical effort and will be responsible for sourcing and evaluating new platform investments and opportunities to acquire or license products. Mr. Poulos most recently served as Vice President, Head of Business Development and Acquisitions for AbbVie.
Mr. Poulos is a veteran pharmaceutical executive who spent more than 38 years with Abbott and AbbVie. His career spanned executive roles in finance, general management, licensing, business development, and acquisitions, including time spent serving as General Manager of Abbott’s Middle East, Africa, and Turkey business. For the last twenty years, Mr. Poulos led teams in business development and acquisitions. During his career, he was instrumental in the execution of numerous acquisitions including Knoll/BASF Pharma in 2001 for $6.9 billion, which led to the development and launch of Humira, Solvay SA’s pharmaceutical arm in 2010 for $6.2 billion, and Pharmacyclics in 2015 for $21.0 billion. Mr. Poulos currently serves on the board of Faron Pharmaceuticals. He holds a Bachelor of Science and a Master in Business Administration from Indiana University.
“John brings a wealth of experience, a track record of successful transactions, and deep relationships across the global pharmaceutical industry,” said Tony Davis, President and Managing Partner at Linden. “He complements our ongoing efforts in both the branded and generic pharmaceutical space.”
“After spending my career with Abbott and AbbVie, I’m thrilled to partner with a healthcare exclusive firm that values my three decades of operational and transactional experience,” said Mr. Poulos. “Over the last several months, we’ve built a strong relationship, and I look forward to continuing with a formal, proactive effort to acquire products and businesses in the pharmaceutical sector.”
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.